Nirmatrelvir Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report
Top Cited Papers
- 19 August 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (2) , 352-355
Abstract
Resistance of SARS-CoV-2 to antivirals was shown to develop in immunocompromised individuals receiving remdesivir. We describe an immunocompromised patient who was treated with repeated and prolonged courses of nirmatrelvir and developed de-novo E166V/L50F mutations in the Mpro region. These mutations were associated with clinical and virological treatment failure.Keywords
This publication has 10 references indexed in Scilit:
- Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistanceEBioMedicine, 2023
- Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatmentNature Communications, 2023
- The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanismsChemical Science, 2023
- Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirNature, 2022
- SARS-CoV-2 in immunocompromised individualsImmunity, 2022
- Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infectionCell Reports Medicine, 2022
- De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case reportNature Communications, 2022
- Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysisAntiviral Research, 2022
- SARS-CoV-2 Variants in Patients with ImmunosuppressionNew England Journal of Medicine, 2021
- SARS-CoV-2 evolution during treatment of chronic infectionNature, 2021